

Clinical Utilization Management Guidelines

Attached is a list of the *Clinical UM Guidelines* the health plan has adopted.

The full list of *Medical Policies* and *Clinical Utilization Management (UM) Guidelines* are publicly available on the [Medical Policy and Clinical UM Guideline subsidiary website](#). Their purpose is to help you provide quality care by reducing inappropriate use of medical resources.

MCG[®] care guidelines are used only for:

- Medical necessity review for medical and behavioral health inpatient review.
- Inpatient site of service appropriateness.
- Inpatient rehabilitation and skilled nursing facility review.
- Outpatient based service or procedure where there is not an established medical policy or clinical UM guideline.

In addition, American Society of Addiction Medicine[®] (ASAM) criteria is used for substance use services according to state requirements.

Medicaid state contracts, regulatory guidance, CMS requirements and our *Medical Policy/Clinical UM Guidelines* supersede MCG care guidelines.

Note: We make determinations of medical necessity on a case-by-case basis in accordance with the definition of medical necessity that is contained within the Medicaid state contract, regulatory guidance, CMS requirements or in our *Medical Necessity Criteria Policy ADMIN.0004*.

If the request does not meet established criteria guidelines, it will be referred to the licensed physician reviewer with the appropriate clinical expertise to make a decision.

Clinical Utilization Management Guidelines

The new *Clinical Utilization Management (UM) Guidelines* below were adopted by the medical operations committee for Healthy Blue members on March 28, 2019. For markets with carved-out pharmacy services, the applicable listings below are informational only.

To view a guideline, visit <https://provider.healthybluelua.com/louisiana-provider/medical-policies-and-clinical-guidelines>.

Clinical UM Guideline #	Clinical UM Guideline title	New item
CG-ADMIN-01	<i>Clinical UM Guideline for Prepayment Review Medical Necessity Determinations When No Other Clinical UM Guideline Exists</i>	
CG-ADMIN-02	<i>Clinically Equivalent Cost Effective Services — Targeted Immune Modulators</i>	
CG-ANC-03	<i>Acupuncture</i>	
CG-ANC-04	<i>Ambulance Services: Air and Water</i>	
CG-ANC-05	<i>Ambulance Services: Ground; Emergent</i>	
CG-ANC-06	<i>Ambulance Services: Ground; Nonemergent</i>	
CG-ANC-07	<i>Inpatient Interfacility Transfers</i>	New
CG-BEH-01	<i>Assessment for Autism Spectrum Disorders and Rett Syndrome</i>	
CG-BEH-02	<i>Adaptive Behavioral Treatment for Autism Spectrum Disorder</i>	
CG-BEH-14	<i>Intensive In-Home Behavioral Health Services</i>	
CG-BEH-15	<i>Activity Therapy for Autism Spectrum Disorders and Rett Syndrome</i>	
CG-DME-01	<i>External (Portable) Continuous Insulin Infusion Pumps</i>	
CG-DME-03	<i>Neuromuscular Stimulation in the Treatment of Muscle Atrophy</i>	
CG-DME-04	<i>Electrical Nerve Stimulation, Transcutaneous, Percutaneous</i>	
CG-DME-05	<i>Cervical Traction Devices for Home Use</i>	
CG-DME-06	<i>Pneumatic Compression Devices for Lymphedema</i>	
CG-DME-07	<i>Augmentative and Alternative Communication Devices/Speech-Generating Devices</i>	
CG-DME-08	<i>Infant Home Apnea Monitors</i>	
CG-DME-09	<i>Continuous Local Delivery of Analgesia to Operative Sites using an Elastomeric Infusion Pump During the Postoperative Period</i>	
CG-DME-10	<i>Durable Medical Equipment</i>	
CG-DME-12	<i>Home Phototherapy Devices for Neonatal Hyperbilirubinemia</i>	
CG-DME-13	<i>Lower Limb Prosthesis</i>	
CG-DME-15	<i>Hospital Beds and Accessories</i>	
CG-DME-16	<i>Pressure Reducing Support Systems Groups 1, 2 and 3</i>	
CG-DME-18	<i>Home Oxygen Therapy</i>	

<https://providers.healthybluelua.com>

Healthy Blue is the trade name of Community Care Health Plan of Louisiana, Inc., an independent licensee of the Blue Cross and Blue Shield Association.

BLAPEC-1765-20 April 2020

CG-DME-19	<i>Therapeutic Shoes, Inserts or Modifications for Individuals with Diabetes</i>	
CG-DME-20	<i>Orthopedic Footwear</i>	
CG-DME-21	<i>External Infusion Pumps for the Administration of Drugs in the Home or Residential Care Settings</i>	
CG-DME-22	<i>Ankle-Foot and Knee-Ankle-Foot Orthotics (Braces)</i>	
CG-DME-23	<i>Lifting Devices for Use in the Home</i>	
CG-DME-24	<i>Wheeled Mobility Devices: Manual Wheelchairs — Standard, Heavy Duty and Lightweight</i>	
CG-DME-25	<i>Seat Lift Mechanisms</i>	
CG-DME-26	<i>Back-Up Ventilators in the Home Setting</i>	
CG-DME-30	<i>Prothrombin Time Self-Monitoring Devices</i>	
CG-DME-31	<i>Wheeled Mobility Devices: Wheelchairs — Powered, Motorized, With or Without Power Seating Systems, and Power Operated Vehicles</i>	
CG-DME-33	<i>Wheeled Mobility Devices: Manual Wheelchairs — Ultra Lightweight</i>	
CG-DME-34	<i>Wheeled Mobility Devices: Wheelchair Accessories</i>	
CG-DME-35	<i>Breastfeeding Pumps</i>	
CG-DME-36	<i>Pediatric Gait Trainers</i>	
CG-DME-37	<i>Air Conduction Hearing Aids</i>	
CG-DME-38	<i>Continuous Interstitial Glucose Monitoring</i>	
CG-DME-39	<i>Dynamic Low-Load Prolonged-Duration Stretch</i>	
CG-DME-41	<i>Ultraviolet Light Therapy Delivery Devices for Home Use</i>	
CG-DME-42	<i>Nonimplantable Insulin Infusion and Blood Glucose Monitoring Devices</i>	
CG-DME-43	<i>High Frequency Chest Compression Devices for Airway Clearance</i>	
CG-DME-44	<i>Electric Tumor Treatment Field (TTF)</i>	
CG-DME-45	<i>Ultrasound Bone Growth Stimulation</i>	
CG-DME-46	<i>Pneumatic Compression Devices for Prevention of Deep Vein Thrombosis of the Lower Limbs</i>	
CG-DRUG-01	<i>Off-Label Drug and Approved Orphan Drug Use</i>	
CG-DRUG-03	<i>Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis</i>	
CG-DRUG-04	<i>Use of Low Molecular Weight Heparin Therapy, Fondaparinux (Arixtra[®]), and Direct Thrombin Inhibitors in the Outpatient Setting</i>	
CG-DRUG-05	<i>Recombinant Erythropoietin Products</i>	
CG-DRUG-08	<i>Enzyme Replacement Therapy for Gaucher Disease</i>	
CG-DRUG-09	<i>Immune Globulin Therapy</i>	
CG-DRUG-11	<i>Infertility Drugs</i>	
CG-DRUG-14	<i>Dihydroergotamine Mesylate (DHE) Injection for the Treatment of Migraine or Cluster Headaches in Adults</i>	
CG-DRUG-16	<i>White Blood Cell Growth Factors</i>	

CG-DRUG-18	<i>Nesiritide (Natrecro®)</i>	
CG-DRUG-19	<i>Progesterone Therapy as a Technique to Prevent Preterm Delivery in High-Risk Women</i>	
CG-DRUG-20	<i>Enfuvirtide (Fuzeon)</i>	
CG-DRUG-21	<i>Naltrexone (Vivitrol®) Injections for the Treatment of Alcohol and Opioid Dependence</i>	
CG-DRUG-24	<i>Repository Corticotropin Injection (H.P. Acthar® Gel)</i>	
CG-DRUG-27	<i>Clostridial Collagenase Histolyticum Injection</i>	
CG-DRUG-28	<i>Alglucosidase alfa (Lumizyme®, Myozyme®)</i>	
CG-DRUG-29	<i>Hyaluronan Injections</i>	
CG-DRUG-33	<i>Palonosetron (Aloxi®)</i>	
CG-DRUG-34	<i>Docetaxel (Docefrez™, Taxotere®)</i>	
CG-DRUG-38	<i>Pemetrexed Disodium (Alimta®)</i>	
CG-DRUG-40	<i>Bortezomib (Velcade®)</i>	
CG-DRUG-41	<i>Zoledronic acid</i>	
CG-DRUG-42	<i>Asparagine Specific Enzymes (Asparaginase)</i>	
CG-DRUG-43	<i>Natalizumab (Tysabri®)</i>	
CG-DRUG-44	<i>Pegloticase (Krystexxa®)</i>	
CG-DRUG-45	<i>Octreotide acetate (Sandostatin®; Sandostatin® LAR Depot)</i>	
CG-DRUG-46	<i>Fosaprepitant (Emend®)</i>	
CG-DRUG-48	<i>Azacitidine (Vidaza®)</i>	
CG-DRUG-49	<i>Doxorubicin Hydrochloride Liposome Injection</i>	
CG-DRUG-50	<i>Paclitaxel, protein-bound (Abraxane®)</i>	
CG-DRUG-51	<i>Romidepsin (Istodax®)</i>	
CG-DRUG-52	<i>Temsirolimus (Torisel®)</i>	
CG-DRUG-53	<i>Drug Dosage, Frequency, and Route of Administration</i>	
CG-DRUG-54	<i>Agalsidase beta (Fabrazyme®)</i>	
CG-DRUG-55	<i>Elosulfase alfa (Vimizim®)</i>	
CG-DRUG-56	<i>Galsulfase (Naglazyme®)</i>	
CG-DRUG-57	<i>Idurasufase (Elaprase®)</i>	
CG-DRUG-58	<i>Laronidase (Aldurazyme®)</i>	
CG-DRUG-59	<i>Testosterone, Injectable</i>	
CG-DRUG-60	<i>Gonadotropin Releasing Hormone Analogs for the Treatment of Oncologic Indications</i>	
CG-DRUG-61	<i>Gonadotropin Releasing Hormone Analogs for the Treatment of Nononcologic Indications</i>	
CG-DRUG-62	<i>Fulvestrant (FASLODEX®)</i>	
CG-DRUG-63	<i>Levoleucovorin Products</i>	
CG-DRUG-64	<i>FDA-Approved Biosimilar Products</i>	
CG-DRUG-65	<i>Tumor Necrosis Factor Antagonists</i>	
CG-DRUG-66	<i>Panitumumab (Vectibix®)</i>	
CG-DRUG-67	<i>Cetuximab (Erbix®)</i>	
CG-DRUG-68	<i>Bevacizumab (Avastin®) for Non-Ophthalmologic Indications</i>	
CG-DRUG-69	<i>Ustekinumab (Stelera®)</i>	

CG-DRUG-70	<i>Eribulin mesylate (Halaven[®])</i>	
CG-DRUG-71	<i>Ziv-aflibercept (Zaltrap[®])</i>	
CG-DRUG-72	<i>Pertuzumab (Perjeta[®])</i>	
CG-DRUG-73	<i>Denosumab (Prolia[®], Xgeva[®])</i>	
CG-DRUG-74	<i>Canakinumab (Ilaris[®])</i>	
CG-DRUG-75	<i>Romiplostim (Nplate[®])</i>	
CG-DRUG-76	<i>Plerixafor Injection (MozobilTM)</i>	
CG-DRUG-77	<i>Radium Ra 223 Dichloride (Xofigo[®])</i>	
CG-DRUG-78	<i>Antihemophilic Factors and Clotting Factors</i>	
CG-DRUG-79	<i>Siltuximab (Sylvant[®])</i>	
CG-DRUG-80	<i>Cabazitaxel (Jevtana[®])</i>	
CG-DRUG-81	<i>Tocilizumab (Actemra[®])</i>	
CG-DRUG-82	<i>Prostacyclin Infusion Therapy and Inhalation Therapy for Treatment of Pulmonary Arterial Hypertension</i>	
CG-DRUG-83	<i>Growth Hormone</i>	
CG-DRUG-84	<i>Belimumab (Benlysta[®])</i>	
CG-DRUG-85	<i>Tesamorelin (Egrifta[®])</i>	
CG-DRUG-86	<i>Ocriplasmin (Jetrea[®]) Intravitreal Injection Treatment</i>	
CG-DRUG-87	<i>Vedolizumab (Entyvio[®])</i>	
CG-DRUG-88	<i>Dupilumab (Dupixent[®])</i>	
CG-DRUG-89	<i>Implantable and Extended-Release Buprenorphine-Containing Products</i>	
CG-DRUG-90	<i>Intravitreal Treatment for Retinal Vascular Conditions</i>	
CG-DRUG-91	<i>Intravitreal Corticosteroid Implants</i>	
CG-DRUG-92	<i>Alpha-1 Proteinase Inhibitor Therapy</i>	
CG-DRUG-93	<i>Sarilumab (Kevzara[®])</i>	
CG-DRUG-94	<i>Rituximab (Rituxan[®]) for Non-Oncologic Indications</i>	
CG-DRUG-95	<i>Belatacept (Nulojix[®])</i>	
CG-DRUG-96	<i>Ado-trastuzumab emtansine (Kadcyla[®])</i>	
CG-DRUG-97	<i>Rilonacept (Arcalyst[®])</i>	
CG-DRUG-98	<i>Bendamustine Hydrochloride</i>	
CG-DRUG-99	<i>Elotuzumab (EmplicitiTM)</i>	
CG-DRUG-100	<i>Interferon gamma-1b (Actimmune[®])</i>	
CG-DRUG-101	<i>Ixabepilone (Ixempra[®])</i>	
CG-DRUG-102	<i>Olaratumab (LartruvoTM)</i>	
CG-DRUG-103	<i>Botulinum Toxin</i>	
CG-DRUG-104	<i>Omalizumab (Xolair[®])</i>	
CG-DRUG-105	<i>Abatacept (Orencia[®])</i>	
CG-DRUG-106	<i>Brentuximab Vedotin (Adcetris[®])</i>	
CG-DRUG-107	<i>Pharmacotherapy for Hereditary Angioedema</i>	
CG-DRUG-108	<i>Enteral Carbidopa and Levodopa Intestinal Gel Suspension</i>	
CG-DRUG-109	<i>Asfotase Alfa (StrensiqTM)</i>	
CG-DRUG-110	<i>Naltrexone Implantable Pellets</i>	
CG-DRUG-111	<i>Sebelipase alfa (KANUMATM)</i>	

CG-DRUG-112	<i>Abaloparatide (Tymlos™) Injection</i>	
CG-DRUG-113	<i>Inotuzumab ozogamicin (Besponsa®)</i>	
CG-GENE-01	<i>Janus Kinase 2 (JAK2)V617F and JAK2 exon 12 Gene Mutation Assays</i>	
CG-GENE-02	<i>Analysis of KRAS Status</i>	
CG-GENE-03	<i>BRAF Mutation Analysis</i>	
CG-GENE-04	<i>Molecular Marker Evaluation of Thyroid Nodules</i>	
CG-GENE-05	<i>Genetic Testing for DMD Mutations (Duchenne or Becker Muscular Dystrophy)</i>	New
CG-GENE-06	<i>Preimplantation Genetic Diagnosis Testing</i>	
CG-GENE-07	<i>BCR-ABL Mutation Analysis</i>	
CG-GENE-08	<i>Genetic Testing for PTEN Hamartoma Tumor Syndrome</i>	
CG-GENE-09	<i>Genetic Testing for CHARGE Syndrome</i>	
CG-LAB-03	<i>Tropism Testing for HIV Management</i>	
CG-LAB-09	<i>Drug Testing or Screening in the Context of Substance Use Disorder and Chronic Pain</i>	
CG-LAB-10	<i>Zika Virus Testing</i>	
CG-LAB-11	<i>Screening for Vitamin D Deficiency in Average Risk Individuals</i>	
CG-LAB-12	<i>Testing for Oral and Esophageal Cancer</i>	
CG-LAB-13	<i>Skin Nerve Fiber Density Testing</i>	
CG-LAB-14	<i>Respiratory Viral Panel Testing in the Outpatient Setting</i>	
CG-MED-02	<i>Esophageal pH Monitoring</i>	
CG-MED-05	<i>Ketogenic Diet for Treatment of Intractable Seizures</i>	
CG-MED-08	<i>Home Enteral Nutrition</i>	
CG-MED-19	<i>Custodial Care</i>	
CG-MED-21	<i>Anesthesia Services and Moderate ("Conscious") Sedation</i>	
CG-MED-23	<i>Home Health</i>	
CG-MED-24	<i>Electromyography and Nerve Conduction Studies</i>	
CG-MED-26	<i>Neonatal Levels of Care</i>	
CG-MED-28	<i>Iontophoresis for Medical Indications</i>	
CG-MED-32	<i>Ancillary Services for Pregnancy Complications</i>	
CG-MED-34	<i>Monitored Anesthesia Care for Gastrointestinal Endoscopic Procedures</i>	
CG-MED-35	<i>Retinal Telescreening Systems</i>	
CG-MED-37	<i>Intensive Programs for Pediatric Feeding Disorders</i>	
CG-MED-38	<i>Inpatient admission for Radiation Therapy for Cervical or Thyroid Cancer</i>	
CG-MED-39	<i>Central (Hip or Spine) Bone Density Measurement and Screening for Vertebral Fractures Using Dual Energy X-Ray Absorptiometry</i>	
CG-MED-40	<i>External Ambulatory Event Monitors to Detect Cardiac Arrhythmias</i>	
CG-MED-41	<i>Moderate to Deep Anesthesia Services for Dental Surgery in the Facility Setting</i>	
CG-MED-42	<i>Maternity Ultrasound in the Outpatient Setting</i>	

CG-MED-44	<i>Holter Monitors</i>	
CG-MED-45	<i>Transrectal Ultrasonography</i>	
CG-MED-46	<i>Electroencephalography and Video Electroencephalographic Monitoring</i>	
CG-MED-47	<i>Fundus Photography</i>	
CG-MED-48	<i>Scrotal Ultrasound</i>	
CG-MED-49	<i>Auditory Brainstem Responses and Evoked Otoacoustic Emissions for Hearing Disorders</i>	
CG-MED-50	<i>Visual, Somatosensory and Motor Evoked Potentials</i>	
CG-MED-51	<i>Three-Dimensional Rendering of Imaging Studies</i>	
CG-MED-52	<i>Allergy Immunotherapy (Subcutaneous)</i>	
CG-MED-53	<i>Cervical Cancer Screening Using Cytology and Human Papillomavirus Testing</i>	
CG-MED-54	<i>Strapping</i>	
CG-MED-55	<i>Level of Care: Advanced Radiologic Imaging</i>	
CG-MED-56	<i>Non-Obstetrical Transvaginal Ultrasonography</i>	
CG-MED-57	<i>Cardiac Stress Testing with Electrocardiogram</i>	
CG-MED-59	<i>Upper Gastrointestinal Endoscopy</i>	
CG-MED-60	<i>Monitored Anesthesia Care and General Anesthesia for Cataract Surgery</i>	
CG-MED-61	<i>Preoperative Testing for Low-Risk Invasive Procedures and Surgeries</i>	
CG-MED-62	<i>Resting Electrocardiogram Screening in Adults</i>	
CG-MED-63	<i>Treatment of Hyperhidrosis</i>	
CG-MED-64	<i>Transcatheter Ablation of Arrhythmogenic Foci in the Pulmonary Veins as a Treatment of Atrial Fibrillation or Atrial Flutter (Radiofrequency and Cryoablation)</i>	
CG-MED-66	<i>Cryopreservation of Oocytes or Ovarian Tissue</i>	
CG-MED-67	<i>Melanoma Vaccines</i>	
CG-MED-68	<i>Therapeutic Apheresis</i>	
CG-MED-69	<i>Inhaled Nitric Oxide</i>	
CG-MED-70	<i>Wireless Capsule Endoscopy for Gastrointestinal Image and the Patency Capsule</i>	
CG-MED-71	<i>Wound Care in the Home Setting</i>	
CG-MED-72	<i>Hyperthermia for Cancer Therapy</i>	
CG-MED-73	<i>Hyperbaric Oxygen Therapy (Systemic/Topical)</i>	
CG-MED-74	<i>Implantable Ambulatory Event Monitors and Mobile Cardiac Telemetry</i>	
CG-MED-75	<i>Medical and Other Non-Behavioral Health Related Treatments for Autism Spectrum Disorders and Rett Syndrome</i>	
CG-MED-76	<i>Magnetic Source Imaging and Magnetoencephalography</i>	
CG-MED-77	<i>SPECT/CT Fusion Imaging</i>	
CG-MED-78	<i>Anesthesia Services for Interventional Pain Management Procedures</i>	

CG-MED-79	<i>Diaphragmatic/Phrenic Nerve Stimulation and Diaphragm Pacing Systems</i>	
CG-MED-80	<i>Positron Emission Tomography (PET) and PET/CT Fusion</i>	
CG-MED-81	<i>High Intensity Focused Ultrasound (HIFU) for Oncologic Indications</i>	
CG-MED-82	<i>Intravenous versus Oral Drug Administration in the Outpatient and Home Setting</i>	
CG-MED-83	<i>Level of Care: Specialty Pharmaceuticals</i>	
CG-OR-PR-02	<i>Prefabricated and Prophylactic Knee Braces</i>	
CG-OR-PR-03	<i>Custom-made Knee Braces</i>	
CG-OR-PR-04	<i>Cranial Remodeling Bands and Helmets (Cranial Orthotics)</i>	
CG-OR-PR-05	<i>Myoelectric Upper Extremity Prosthesis Devices</i>	
CG-OR-PR-06	<i>Spinal Orthoses: Thoracic-Lumber-Sacral (TLSO), Lumber-Sacral (LSO), and Lumber</i>	
CG-REHAB-02	<i>Outpatient Cardiac Rehabilitation</i>	
CG-REHAB-03	<i>Pulmonary Rehabilitation</i>	
CG-REHAB-04	<i>Physical Therapy</i>	
CG-REHAB-05	<i>Occupational Therapy</i>	
CG-REHAB-06	<i>Speech-Language Pathology Services</i>	
CG-REHAB-07	<i>Skilled Nursing and Skilled Rehabilitation Services (Outpatient)</i>	
CG-REHAB-08	<i>Private Duty Nursing in the Home Setting</i>	
CG-REHAB-10	<i>Level of Care: Outpatient Physical Therapy, Occupational Therapy and</i>	
CG-REHAB-11	<i>Cognitive Rehabilitation</i>	
CG-SURG-01	<i>Colonoscopy</i>	
CG-SURG-03	<i>Blepharoplasty, Blepharoptosis Repair and Brow Lift</i>	
CG-SURG-05	<i>Maze Procedure</i>	
CG-SURG-07	<i>Vertical Expandable Prosthetic Titanium Rib</i>	
CG-SURG-08	<i>Sacral Nerve Stimulation as a Treatment of Neurogenic Bladder Secondary to Spinal Cord Injury</i>	
CG-SURG-09	<i>Temporomandibular Disorders</i>	
CG-SURG-10	<i>Ambulatory or Outpatient Surgery Center Procedures</i>	
CG-SURG-11	<i>Surgical Treatment for Dupuytren's Contracture</i>	
CG-SURG-12	<i>Penile Prosthesis Implantation</i>	
CG-SURG-15	<i>Endometrial Ablation</i>	
CG-SURG-17	<i>Trigger Point Injections</i>	
CG-SURG-18	<i>Septoplasty</i>	
CG-SURG-24	<i>Functional Endoscopic Sinus Surgery</i>	
CG-SURG-25	<i>Injection Treatment for Morton's Neuroma</i>	
CG-SURG-27	<i>Sex Reassignment Surgery</i>	
CG-SURG-28	<i>Transcatheter Uterine Artery Embolization</i>	
CG-SURG-29	<i>Lumbar Discography</i>	
CG-SURG-30	<i>Tonsillectomy with or without Adenoidectomy for Children</i>	
CG-SURG-31	<i>Treatment of Keloids and Scar Revision</i>	

CG-SURG-34	<i>Diagnostic Infertility Surgery</i>	
CG-SURG-35	<i>Intracytoplasmic Sperm Injection (ICSI)</i>	
CG-SURG-36	<i>Adenoidectomy</i>	
CG-SURG-37	<i>Destruction of Pre-Malignant Skin Lesions</i>	
CG-SURG-40	<i>Cataract Removal Surgery for Adults</i>	
CG-SURG-41	<i>Surgical Strabismus Correction</i>	
CG-SURG-46	<i>Myringotomy and Tympanostomy Tube Insertion</i>	
CG-SURG-49	<i>Endovascular Techniques (Percutaneous or Open Exposure) for Arterial Revascularization of the Lower Extremities</i>	
CG-SURG-50	<i>Assistant Surgeons</i>	
CG-SURG-51	<i>Outpatient Cystourethroscopy</i>	
CG-SURG-52	<i>Level of Care: Hospital-Based Ambulatory Surgical Procedures, including Endoscopic Procedures</i>	
CG-SURG-55	<i>Intracardiac Electrophysiological Studies and Catheter Ablation</i>	
CG-SURG-56	<i>Diagnostic Fiberoptic Flexible Laryngoscopy</i>	
CG-SURG-57	<i>Diagnostic Nasal Endoscopy</i>	
CG-SURG-58	<i>Radioactive Seed Localization of Nonpalpable Breast Lesions</i>	
CG-SURG-59	<i>Vena Cava Filters</i>	
CG-SURG-61	<i>Cryosurgical Ablation of Solid Tumors Outside the Liver</i>	
CG-SURG-62	<i>Radiofrequency Ablation to Treat Tumors Outside the Liver</i>	
CG-SURG-63	<i>Cardiac Resynchronization Therapy (CRT) with or without an Implantable Cardioverter Defibrillator (CRT/ICD) for the Treatment of Heart Failure</i>	
CG-SURG-70	<i>Gastric Electrical Stimulation</i>	
CG-SURG-71	<i>Reduction Mammoplasty</i>	
CG-SURG-72	<i>Endothelial Keratoplasty</i>	
CG-SURG-73	<i>Balloon Sinus Ostial Dilation</i>	
CG-SURG-74	<i>Total Ankle Replacement</i>	
CG-SURG-75	<i>Transanal Endoscopic Microsurgical (TEM) Excision of Rectal Lesions</i>	
CG-SURG-76	<i>Carotid, Vertebral and Intracranial Artery Stent Placement with or without Angioplasty</i>	
CG-SURG-77	<i>Refractive Surgery</i>	
CG-SURG-78	<i>Locally Ablative Techniques for Treating Primary and Metastatic Liver Malignancies</i>	
CG-SURG-79	<i>Implantable Infusion Pumps</i>	
CG-SURG-80	<i>Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Embolization (TAE) for Treating Primary or Metastatic Liver Tumors</i>	
CG-SURG-81	<i>Cochlear Implants and Auditory Brainstem Implants</i>	
CG-SURG-82	<i>Bone-Anchored and Bone Conduction Hearing Aids</i>	
CG-SURG-83	<i>Bariatric Surgery and Other Treatments for Clinically Severe Obesity</i>	
CG-SURG-84	<i>Mandibular/Maxillary (Orthognathic) Surgery</i>	
CG-SURG-85	<i>Hip Resurfacing</i>	

CG-SURG-86	<i>Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection</i>	
CG-SURG-87	<i>Nasal Surgery for the Treatment of Obstructive Sleep Apnea and Snoring</i>	
CG-SURG-88	<i>Mastectomy for Gynecomastia</i>	
CG-SURG-89	<i>Radiofrequency Neurolysis and Pulsed Radiofrequency Therapy for Trigeminal Neuralgia</i>	
CG-SURG-90	<i>Mohs Micrographic Surgery</i>	
CG-SURG-91	<i>Minimally Invasive Ablative Procedures for Epilepsy</i>	
CG-SURG-92	<i>Paraesophageal Hernia Repair</i>	New
CG-SURG-93	<i>Angiographic Evaluation and Endovascular Intervention for Dialysis Access Circuit Dysfunction</i>	New
CG-SURG-94	<i>Keratoprosthesis</i>	New
CG-SURG-95	<i>Sacral Nerve Stimulation and Percutaneous Tibial Nerve Stimulation for Urinary and Fecal Incontinence; Urinary Retention</i>	New
CG-SURG-96	<i>Intraocular Telescope</i>	New
CG-SURG-97	<i>Cardioverter Defibrillators</i>	
CG-SURG-98	<i>Prostate Multiparametric Magnetic Resonance Imaging</i>	
CG-SURG-99	<i>Panniculectomy and Abdominoplasty</i>	
CG-THER-RAD-03	<i>Radioimmunotherapy and Somatostatin Receptor Targeted Radiotherapy</i>	
CG-THER-RAD-04	<i>Selective Internal Radiation Therapy of Primary or Metastatic Liver Tumors</i>	
CG-THER-RAD-07	<i>Intravascular Brachytherapy (Coronary and Non-Coronary)</i>	
CG-TRANS-02	<i>Kidney Transplantation</i>	
CG-TRANS-03	<i>Donor Lymphocyte Infusion for Hematologic Malignancies after Allogeneic Hematopoietic Progenitor Cell Transplantation</i>	